Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML

Executive Summary

Pfizer Inc.'s Bosulif (bosutinib) will now become generally available on the UK's publicly-funded NHS for use in certain types of chronic myeloid leukemia after NICE reassessed the tyrosine kinase inhibitor in light of new data and a bigger pro-offered price discount from its manufacturer. The drug was previously only available through the country's controversial Cancer Drugs Fund (CDF).

You may also be interested in...



Back to 2010: England's New CDF To Go Ahead

England's new Cancer Drugs Fund is to go ahead with little change to proposals that have proved unpopular with companies. The Association of the British Pharmaceutical Industry says the new system will take patients and companies back to the situation in 2010 before the CDF was set up and that two thirds of CDF-financed drugs will be unavailable by the end of the year. Eisai has slammed the new fund, warning that drugs approved after the CDF closed its doors to funding new products will float in limbo with no clear means of getting to patients.

Pfizer faces more Bosulif bother as NICE issues final no

NICE, the health technology appraisal institute for England and Wales, has joined the growing swell of European HTAs rejecting Pfizer's chronic myeloid leukemia (CML) drug Bosulif (bosutinib).

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel